These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11162238)

  • 1. Coexpression of human cdk5 and its activator p35 with human protein tau in neurons in brain of triple transgenic mice.
    Van den Haute C; Spittaels K; Van Dorpe J; Lasrado R; Vandezande K; Laenen I; Geerts H; Van Leuven F
    Neurobiol Dis; 2001 Feb; 8(1):32-44. PubMed ID: 11162238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5.
    Ahlijanian MK; Barrezueta NX; Williams RD; Jakowski A; Kowsz KP; McCarthy S; Coskran T; Carlo A; Seymour PA; Burkhardt JE; Nelson RB; McNeish JD
    Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2910-5. PubMed ID: 10706614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The levels of cdk5 and p35 proteins and tau phosphorylation are reduced during neuronal apoptosis.
    Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T
    Biochem Biophys Res Commun; 2001 Feb; 280(4):998-1002. PubMed ID: 11162625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of cyclin-dependent kinase-5 activity on apoptosis and tau phosphorylation in immortalized mouse brain cortical cells.
    Shelton SB; Krishnamurthy P; Johnson GV
    J Neurosci Res; 2004 Apr; 76(1):110-20. PubMed ID: 15048935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice.
    Hallows JL; Chen K; DePinho RA; Vincent I
    J Neurosci; 2003 Nov; 23(33):10633-44. PubMed ID: 14627648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro.
    Town T; Zolton J; Shaffner R; Schnell B; Crescentini R; Wu Y; Zeng J; DelleDonne A; Obregon D; Tan J; Mullan M
    J Neurosci Res; 2002 Aug; 69(3):362-72. PubMed ID: 12125077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration.
    Patrick GN; Zukerberg L; Nikolic M; de la Monte S; Dikkes P; Tsai LH
    Nature; 1999 Dec; 402(6762):615-22. PubMed ID: 10604467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease.
    Hallows JL; Iosif RE; Biasell RD; Vincent I
    J Neurosci; 2006 Mar; 26(10):2738-44. PubMed ID: 16525053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic contributions of cyclin-dependant kinase 5/p35 and Reelin/Dab1 to the positioning of cortical neurons in the developing mouse brain.
    Ohshima T; Ogawa M; Veeranna ; Hirasawa M; Longenecker G; Ishiguro K; Pant HC; Brady RO; Kulkarni AB; Mikoshiba K
    Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2764-9. PubMed ID: 11226314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology.
    Maccioni RB; Otth C; Concha II; Muñoz JP
    Eur J Biochem; 2001 Mar; 268(6):1518-27. PubMed ID: 11248668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons.
    Li G; Faibushevich A; Turunen BJ; Yoon SO; Georg G; Michaelis ML; Dobrowsky RT
    J Neurochem; 2003 Jan; 84(2):347-62. PubMed ID: 12558997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model.
    Bu B; Li J; Davies P; Vincent I
    J Neurosci; 2002 Aug; 22(15):6515-25. PubMed ID: 12151531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A brain-specific activator of cyclin-dependent kinase 5.
    Lew J; Huang QQ; Qi Z; Winkfein RJ; Aebersold R; Hunt T; Wang JH
    Nature; 1994 Sep; 371(6496):423-6. PubMed ID: 8090222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The protective effects of tanshinone IIA on neurotoxicity induced by β-amyloid protein through calpain and the p35/Cdk5 pathway in primary cortical neurons.
    Shi LL; Yang WN; Chen XL; Zhang JS; Yang PB; Hu XD; Han H; Qian YH; Liu Y
    Neurochem Int; 2012 Jul; 61(2):227-35. PubMed ID: 22561406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial rescue of the p35-/- brain phenotype by low expression of a neuronal-specific enolase p25 transgene.
    Patzke H; Maddineni U; Ayala R; Morabito M; Volker J; Dikkes P; Ahlijanian MK; Tsai LH
    J Neurosci; 2003 Apr; 23(7):2769-78. PubMed ID: 12684463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia.
    Seo J; Kritskiy O; Watson LA; Barker SJ; Dey D; Raja WK; Lin YT; Ko T; Cho S; Penney J; Silva MC; Sheridan SD; Lucente D; Gusella JF; Dickerson BC; Haggarty SJ; Tsai LH
    J Neurosci; 2017 Oct; 37(41):9917-9924. PubMed ID: 28912154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p35 and Rac1 underlie the neuroprotection and cognitive improvement induced by CDK5 silencing.
    Posada-Duque RA; López-Tobón A; Piedrahita D; González-Billault C; Cardona-Gomez GP
    J Neurochem; 2015 Jul; 134(2):354-70. PubMed ID: 25864429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.
    Kesavapany S; Zheng YL; Amin N; Pant HC
    Biotechnol J; 2007 Aug; 2(8):978-87. PubMed ID: 17526058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The protein SET binds the neuronal Cdk5 activator p35nck5a and modulates Cdk5/p35nck5a activity.
    Qu D; Li Q; Lim HY; Cheung NS; Li R; Wang JH; Qi RZ
    J Biol Chem; 2002 Mar; 277(9):7324-32. PubMed ID: 11741927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells.
    Zheng YL; Li BS; Amin ND; Albers W; Pant HC
    Eur J Biochem; 2002 Sep; 269(18):4427-34. PubMed ID: 12230554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.